2022 Compound Screening FDA Approval 
Drug Discovery World
OCTOBER 4, 2022
Using its proprietary compound screening platform, Oligomerix discovers and develops differentiated, oral, small molecule inhibitors of tau self-association that are easy to administer and cost-effective. . million in 2022 to 12.7 Volume 23 – Issue 4, Fall 2022. million by 2050.” . About the author .
Broad Institute
JULY 26, 2022
Resources, services, and tools By Maria Nemchuk July 26, 2022 Breadcrumb Home Resources, services, and tools Key scientific datasets and computational tools developed by our scientists and their collaborators. Learn more PRISM Rapid, high-throughput multiplexed compound screening in genomically characterized human cancer cell-line models.
Expert insights. Personalized for you.
130 
Let's personalize your content